Loading...
XTAI1731
Market cap92mUSD
Dec 25, Last price  
22.70TWD
1D
0.00%
1Q
-4.81%
Jan 2017
66.06%
Name

Maywufa Co Ltd

Chart & Performance

D1W1MN
XTAI:1731 chart
P/E
17.84
P/S
2.32
EPS
1.27
Div Yield, %
4.85%
Shrs. gr., 5y
—
Rev. gr., 5y
2.97%
Revenues
1.30b
+4.47%
2,858,709,0003,009,097,0002,247,147,0002,146,907,0001,512,329,0001,232,868,0001,369,188,0001,443,068,0001,575,078,0001,123,398,0001,100,863,0001,065,325,0001,289,211,0001,245,105,0001,300,721,000
Net income
169m
+4.49%
57,629,00058,107,00042,090,00059,721,00063,573,00080,524,00079,086,00090,733,00085,937,00075,765,000100,605,000171,002,000164,321,000161,830,000169,098,000
CFO
244m
+65.21%
-12,393,00091,476,00051,699,000269,007,000122,416,000203,800,000155,604,00067,022,000225,630,000228,458,000217,457,000240,462,000262,975,000147,884,000244,319,000
Dividend
Jun 28, 20241.15 TWD/sh
Earnings
May 29, 2025

Profile

Maywufa Company Ltd. manufactures and sells hair and skin care products under the Maywufa brand in Taiwan. It offers hair care products; health care products and food supplements; and mother and baby skin care products under the mustela brand. The company also provides pharmaceuticals and medical devices, such as PG2 Lyophilized injection for treatment of cancer-related fatigue; AmCad-UT Detection device, an ultrasound CAD for thyroid cancer detection; Bio-Three tablets for the treatment of mild diarrhea, abdominal pain, and constipation; and Cerebrolysin, a supplementary nutrient boost for patients who cannot ingest adequate food and patients who have difficulties in the digestion, absorption, synthesis, and utilization of proteins, as well as for patients suffering from severe trauma, burns, fractures, insufficient protein intake, or malnutrition. In addition, it sells and distributes pharmaceutical products; and operates and manages pharmacy chain under the Pharmacy Franchise name. Maywufa Company Ltd. was founded in 1976 and is headquartered in Taipei, Taiwan.
URL
https://www.maywufa.com.tw/
IPO date
Sep 17, 2001
Employees
Domiciled in
TW
Incorporated in
TW

Valuation

Title
TWD in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑122015‑122014‑12
Income
Revenues
1,300,721
4.47%
1,245,105
-3.42%
1,289,211
21.02%
Cost of revenue
1,105,374
1,046,598
1,072,318
Unusual Expense (Income)
NOPBT
195,347
198,507
216,893
NOPBT Margin
15.02%
15.94%
16.82%
Operating Taxes
41,150
46,523
47,461
Tax Rate
21.07%
23.44%
21.88%
NOPAT
154,197
151,984
169,432
Net income
169,098
4.49%
161,830
-1.52%
164,321
-3.91%
Dividends
(146,207)
(155,511)
(132,916)
Dividend yield
4.89%
5.92%
5.10%
Proceeds from repurchase of equity
BB yield
Debt
Debt current
3,689
8,418
10,572
Long-term debt
443,625
227,151
323,544
Deferred revenue
Other long-term liabilities
1,945
1,893
1,893
Net debt
(760,963)
(569,174)
(611,606)
Cash flow
Cash from operating activities
244,319
147,884
262,975
CAPEX
(251,559)
(230,393)
(5,614)
Cash from investing activities
(308,390)
36,198
(210,952)
Cash from financing activities
66,518
(245,539)
(140,292)
FCF
(100,428)
(88,801)
212,164
Balance
Cash
573,611
584,378
879,670
Long term investments
634,666
220,365
66,052
Excess cash
1,143,241
742,488
881,261
Stockholders' equity
1,847,836
1,808,951
1,817,948
Invested Capital
1,338,526
1,463,135
1,405,209
ROIC
11.01%
10.60%
12.52%
ROCE
7.87%
9.00%
9.49%
EV
Common stock shares outstanding
133,267
132,915
133,315
Price
22.45
13.67%
19.75
1.02%
19.55
12.03%
Market cap
2,991,844
13.97%
2,625,071
0.72%
2,606,308
11.96%
EV
2,230,881
2,055,897
1,994,702
EBITDA
224,142
227,788
247,922
EV/EBITDA
9.95
9.03
8.05
Interest
92
2,561
5,312
Interest/NOPBT
0.05%
1.29%
2.45%